Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC.
Lai GGY, Yeo JC, Jain A, Zhou S, Pang M, Alvarez JJS, Sim NL, Tan AC, Suteja L, Lim TW, Guo YA, Shen M, Saw SPL, Rohatgi N, Yeong JPS, Takano A, Lim KH, Gogna A, Too CW, Da Zhuang K, Tan WL, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Wang L, Toh CK, Lim WT, Tam WL, Tan SH, Skanderup AMJ, Tan EH, Tan DSW. Lai GGY, et al. Among authors: ng qs. JTO Clin Res Rep. 2022 Sep 21;3(12):100416. doi: 10.1016/j.jtocrr.2022.100416. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36426287 Free PMC article.
Truth about ERCC1 in lung cancer.
Tan DS, Ng QS, Tan IB, Lim ST, Lim WT. Tan DS, et al. Among authors: ng qs. J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159806 No abstract available.
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers.
Tan EH, Goh C, Lim WT, Soo KC, Khoo ML, Tan T, Tan DS, Ang MK, Ng QS, Tan PH, Lim A, Hwang J, Teng YH, Lim TH, Tan SH, Baskaran N, Hui KM. Tan EH, et al. Among authors: ng qs. Ann Oncol. 2012 Apr;23(4):1010-6. doi: 10.1093/annonc/mdr327. Epub 2011 Jul 18. Ann Oncol. 2012. PMID: 21768327 Free article. Clinical Trial.
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST. Ng KP, et al. Among authors: ng qs. Nat Med. 2012 Mar 18;18(4):521-8. doi: 10.1038/nm.2713. Nat Med. 2012. PMID: 22426421
82 results